Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paquinimod - Active Biotech

Drug Profile

Paquinimod - Active Biotech

Alternative Names: 57-57; ABR-215757; SLE 57-57

Latest Information Update: 07 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Class Amides; Anti-inflammatories; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Calgranulin B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Systemic scleroderma
  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 07 Dec 2018 Active Biotech plans a phase II trial for Systemic scleroderma
  • 06 Dec 2018 Active Biotech reactivates development of Paquinimod in Systemic scleroderma in Germany (PO) (Active Biotech pipeline, December 2018)
  • 06 Dec 2018 Active Biotech reactivates development of Paquinimod in Systemic scleroderma in Sweden (PO) (Active Biotech pipeline, December 2018)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top